The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047, a potential first-in-class small-molecule degrader targeting BRD4, by Hangzhou-based Ranok Therapeutics Co., Ltd, has been accepted for review. This marks a significant step forward in the development of innovative cancer treatments.
Discovery and Mechanism of Action
RNK05047 was discovered on Ranok’s proprietary protein degradation platform, CHAMP. BRD4 is a key regulator of oncogenes such as MYC and BCL2, and is involved in the occurrence and development of various cancers. By targeting BRD4, RNK05047 aims to disrupt the cancer-promoting activities of these oncogenes, offering a novel approach to cancer therapy.
Clinical Trial Progress
The drug initiated a Phase I/II study in the US in August last year. The study is designed to assess the safety and tolerability of RNK05047 in patients with advanced solid tumors and lymphomas, as well as to determine the Phase II dosage. This clinical trial is crucial for understanding the drug’s potential in treating various forms of cancer and for advancing its development towards broader clinical use.-Fineline Info & Tech
